Predictive and prognostic effect of ABO blood group on immune checkpoint inhibitors

Ergün, Yakup; Esen, Seli̇n Aktürk; Bardakci, Murat; Uçar, Gökhan; Kalkan, Ziya; Urakçı, Zuhat; Seyran, Erdogan; Doğan, Mutlu; Eren, Tulay; Aslan, Volkan; Kahraman, Seda; Genc, Emine Eylem; Açıkgöz, Yusuf; Dirikoç, Merve; Esen, İrfan; Uncu, Doğan

doi:10.3233/cbm-210455

Cited by 3 publications

(5 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is also found that the efficacy of immune checkpoint inhibitors (ICIs) could be influenced by the ABO blood group, and advanced malignant melanoma patients with type B or AB had significantly longer overall survival (OS) than other blood types after using ICIs. 52 Similar findings have been found in other blood group systems. For example, CD44, which is identical to the blood group antigen In b, is associated with lymphocyte (T cell) activation, hematopoietic development, and metastasis of malignant lymphoma.…”

Section: Methodssupporting

confidence: 82%

ABO Blood Group and the Risk and Prognosis of Lymphoma

Qin¹,

Gao²,

Wang³

et al. 2023

JIR

View full text Add to dashboard Cite

ABO blood group antigens exhibit alternative phenotypes and genetically derived structures that are located on the red cell surface. The role of ABO blood group in cancer biology has been intensely reported by several studies, and it is now widely recognized that ABO antigens are associated with the risk and prognosis of several types of tumors, namely gastric cancer and pancreatic cancer. However, there have been contentious limited issues with the association between the ABO blood group and lymphoma. In this narrative review, based on literature data, we discuss the role of ABO blood group in the risk and prognosis of lymphoma and summarize the current knowledge of the underlying pathogenic mechanisms of the association. The possible association of ABO blood group with racial disparities and pathological classification in lymphoma patients is also discussed.

show abstract

Section: Methodssupporting

confidence: 82%

ABO Blood Group and the Risk and Prognosis of Lymphoma

Qin¹,

Gao²,

Wang³

et al. 2023

JIR

View full text Add to dashboard Cite

show abstract

“…Furthermore, it is worth considering that by combining rs659104 into the haplotype analysis, certain patient populations with an extended OS and PFS after ICI treatment could be identified. Additionally, a study involving 73 patients with advanced melanoma highlighted the significant advantage of antigen B presence on survival 32 . Discrepancies in cancer types (only one melanoma case in the current study), sample size, and research ethnicity might contribute to the differing results.…”

Section: Discussionmentioning

confidence: 82%

“…Additionally, a study involving 73 patients with advanced melanoma highlighted the significant advantage of antigen B presence on survival. 32 Discrepancies in cancer types (only one melanoma case in the current study), sample size, and research ethnicity might contribute to the differing results.…”

Section: Discussionmentioning

confidence: 83%

Blood Group Antigen A Carriers Exhibit an Extended Progression‐Free Survival with no more Immune‐Related Adverse Events

Xiao,

Liu,

Luo

et al. 2023

Clin Pharma and Therapeutics

View full text Add to dashboard Cite

Extensive investigations have been conducted regarding the potential correlation between blood type and the immune system, as well as cancer risk in the Southern Chinese population. However, the prognostic value of the blood group and its genetic determinants in the context of immune checkpoint inhibitor (ICI) treatment remains unclear. Therefore, the associations between the ABO blood group and its single nucleotide polymorphisms (SNPs) were examined in relation to ICI treatment outcomes in 370 eligible patients with cancer. This approach allowed us to derive the blood group from the SNPs responsible for blood group determination. In the discovery cohort (N = 168), antigen A carriers (blood types A and AB) exhibited an extended progression‐free survival (PFS; hazard ratio (HR) = 0.58, 95% confidence interval (CI) = 0.34–0.98). The association results from the SNP‐derived blood were consistent with those from the measured blood group. In the validation cohort (N = 202), Cox regression analysis revealed that the antigen A carriers (rs507666 AA+GA genotype carriers) experienced significantly extended PFS compared with the non‐antigen A carriers (HR = 0.61, 95% CI = 0.40–0.93). Therefore, a longer PFS was observed in antigen A carriers (P value = 0.003, HR = 0.60, 95% CI = 0.44–0.84). Furthermore, haplotype 2 carriers (rs507666 GA and rs659104 GG) demonstrated both extended PFS and improved overall survival. Notably, the presence of antigen A was not associated with the occurrence of overall immune‐related adverse events (irAEs) or organ‐specific toxicity. In summary, our findings revealed that antigen A carriers did not experience a higher incidence of irAEs while exhibiting better immunotherapy efficacy.

show abstract

“…In that study, we investigated the predictive and prognostic effects of the ABO blood group in patients using nivolumab as a single agent in advanced melanoma. 8 In patients with melanoma, the longest PFS and the longest OS were observed in patients with blood group B (16.1 and 20.3 months for PFS and OS, respectively). However, a comparison of the 4 arms showed no significant difference.…”

Section: Discussionmentioning

confidence: 90%

“…In that study, the survival and response rates were found to be better with ICI treatment in patients with the B antigen. 8 In this study, we investigated the predictive and prognostic value of the ABO blood group system in patients who were administered ICIs for treating advanced RCC. This is the first study conducted on patients with RCC.…”

mentioning

confidence: 99%

Predictive and Prognostic Value of ABO Blood Group in Patients Using Immune Checkpoint Inhibitor for Advanced Renal Cell Carcinoma

ERGÜN¹,

UÇAR²,

ESEN³

et al. 2022

J Oncol Sci

Self Cite

View full text Add to dashboard Cite

We investigated the prognostic and predictive effects of the ABO blood group system on patients receiving immune checkpoint inhibitors for advanced renal cell carcinoma (RCC). Material and Methods: In this retrospective observational study, the data on the patients with known ABO blood group, who were administered nivolumab for mRCC, were reviewed. The tumor response rates and survival were analyzed based on the ABO blood group. Results: A total of 89 patients were included in the study. The median age of the patients was 57 (range: 24-83 years) years, and 67% (n=60) of the patients were male. Moreover, 43%, 18%, 9%, and 30% of the patients had blood groups A, B, AB, and O, respectively. Our study had a median follow-up time of 11 months. Although the groups did not differ significantly in progression-free survival (PFS) and overall survival (OS) according to the blood groups, patients who had the B blood type survived longer. For patients with blood types A, B, AB, and O, the median PFS was 5.3 months, 8.4 months, 3.7 months, and 7.8 months, respectively (p=0.8), and the median OS was 14.5 months, 20.3 months, 12.0 months, and 16.5 months, respectively (p=0.8). Conclusion: Although the groups did not differ significantly according to the ABO blood group, the patients with the B blood group survived relatively longer. These results suggested that further studies with more patients should be conducted.

show abstract

Predictive and prognostic effect of ABO blood group on immune checkpoint inhibitors

Cited by 3 publications

References 20 publications

ABO Blood Group and the Risk and Prognosis of Lymphoma

ABO Blood Group and the Risk and Prognosis of Lymphoma

Blood Group Antigen A Carriers Exhibit an Extended Progression‐Free Survival with no more Immune‐Related Adverse Events

Predictive and Prognostic Value of ABO Blood Group in Patients Using Immune Checkpoint Inhibitor for Advanced Renal Cell Carcinoma

Contact Info

Product

Resources

About